Advances in epigenetic therapies for B-cell non-hodgkin lymphoma

IF 3 3区医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2024-12-09 DOI:10.1007/s00277-024-06131-x

Weiwen Hu, Lanlan Zang, Xiaoxi Feng, Shuhui Zhuang, Liudi Chang, Yongjing Liu, Jinyan Huang, Yuanyuan Zhang

{"title":"Advances in epigenetic therapies for B-cell non-hodgkin lymphoma","authors":"Weiwen Hu, Lanlan Zang, Xiaoxi Feng, Shuhui Zhuang, Liudi Chang, Yongjing Liu, Jinyan Huang, Yuanyuan Zhang","doi":"10.1007/s00277-024-06131-x","DOIUrl":null,"url":null,"abstract":"<div><p>B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30–40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 12","pages":"5085 - 5101"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-024-06131-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30–40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

b细胞非霍奇金淋巴瘤的表观遗传治疗进展。

B细胞非霍奇金淋巴瘤（B- nhl）是一类起源于B淋巴细胞的肿瘤。b - nhl可发生在正常b细胞发育的任何阶段，大多数起源于生发中心（如弥漫性大b细胞淋巴瘤、DLBCL和滤泡性淋巴瘤）。标准的初始治疗通常包括化学免疫治疗方案。虽然有很高的初始缓解率，但30-40%的高危患者往往因耐药而面临复发或难治性淋巴瘤。最近的研究揭示了b - nhl的发育与多种表观遗传过程之间的重要联系，如DNA甲基化、组蛋白修饰、非编码rna调控和染色质重塑。针对这些表观遗传变化的治疗在临床研究中显示出相当大的潜力。本文探讨了表观遗传调控对B-NHLs发生和发展的影响。本文讨论了目前与这些表观遗传机制相关的治疗靶点和药物，旨在为靶向治疗和联合化疗治疗B-NHLs提供新的视角和方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.